Physician profile

Alan G Schaffert

Neurology (Psychiatry & Neurology) · Modesto, CA

NPI 1326055880

$3,457.65

in general payments reported to CMS, 2019-2025

34 companies · none reported in 2025

See the full distribution for Neurology (Psychiatry & Neurology)

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ucb, INC. $481.26 2019-2022
Biogen, INC. $322.22 2019-2022
Janssen Pharmaceuticals, INC $304.92 2021
Sunovion Pharmaceuticals INC. $284.96 2019-2021
Novartis Pharmaceuticals Corporation $237.74 2020-2021
Livanova USA, INC. $222.67 2019-2021
Abbvie INC. $219.61 2021
Teva Pharmaceuticals USA, INC. $148.97 2019-2021
Biohaven Pharmaceuticals, INC. $128.99 2020-2021
Adamas Pharmaceuticals, INC. $124.32 2019-2021
Alexion Pharmaceuticals, INC. $117.26 2019-2021
Emd Serono, INC. $111.51 2019-2021
Tanabe Pharma America, INC. $100.00 2019
Acadia Pharmaceuticals INC $71.05 2021
Kyowa Kirin, INC. $54.18 2020-2021
Show all 34 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alan G Schaffert

$3,457.65

in general payments reported 2019-2025

Years
2019-2022
Top company
Ucb, INC.

https://glasscript.com/doctor/104914/alan-g-schaffert

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.